Literature DB >> 18601595

Cardiovascular biomarkers: increasing impact of laboratory medicine in cardiology practice.

Simona Vittorini1, Aldo Clerico.   

Abstract

The practice of cardiology is in continual evolution, in parallel with the progress achieved by medical research in understanding the pathophysiology of cardiovascular disease and in developing new therapeutic procedures. Consequently, manufacturers of cardiac biomarkers are pressed with new demands to improve the performance of the existing and the development of novel ones. Several highly sensitive and/or specific assays for myocardial ischemic damage and myocardial function detection have already become commercially available. Moreover, an increasing number of novel risk factors have been added to the classical risk factors of cardiovascular disease. Finally, the recent surge of genetic analysis procedures will likely soon provide the clinical cardiologist with a number of laboratory tests for defining the molecular diagnosis, assessing new risk factors, and better targeting the pharmaceutical approaches in patients with cardiovascular disease. In this review, we first present the general characteristics of a biomarker followed by the analytical and clinical performance of assay methods.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18601595     DOI: 10.1515/CCLM.2008.188

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  7 in total

Review 1.  Biomarkers in systemic sclerosis.

Authors:  Susan V Castro; Sergio A Jimenez
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

2.  Point-of-care test of heart-type fatty acid-binding protein for the diagnosis of early acute myocardial infarction.

Authors:  Chun-jian Li; Jie-qi Li; Xiao-fang Liang; Xiao-xiang Li; Jian-guo Cui; Zhi-jian Yang; Qing Guo; Ke-jiang Cao; Jun Huang
Journal:  Acta Pharmacol Sin       Date:  2010-02-05       Impact factor: 6.150

3.  Patients with cardiorenal syndrome revealed increased neurohormonal activity, tubular and myocardial damage compared to heart failure patients with preserved renal function.

Authors:  Alberto Palazzuoli; Gaetano Ruocco; Marco Pellegrini; Simona Martini; Gabriele Del Castillo; Matteo Beltrami; Beatrice Franci; Barbara Lucani; Ranuccio Nuti
Journal:  Cardiorenal Med       Date:  2014-12-10       Impact factor: 2.041

Review 4.  Natriuretic Peptides and Troponins to Predict Cardiovascular Events in Patients Undergoing Major Non-Cardiac Surgery.

Authors:  Marco Alfonso Perrone; Alberto Aimo; Sergio Bernardini; Aldo Clerico
Journal:  Int J Environ Res Public Health       Date:  2022-04-24       Impact factor: 4.614

5.  Predicting outcomes in acute coronary syndrome using biochemical markers.

Authors:  P Karki; K K Agrawaal; M Lamsal; N R Shrestha
Journal:  Indian Heart J       Date:  2015-10-26

6.  Identifying a role for the interaction of homocysteine and copper in promoting cardiovascular-related damage.

Authors:  Megha Gupta; Jiries Meehan-Atrash; Robert M Strongin
Journal:  Amino Acids       Date:  2021-04-22       Impact factor: 3.520

7.  ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure.

Authors:  Nadia Aspromonte; Michele Massimo Gulizia; Aldo Clerico; Giuseppe Di Tano; Michele Emdin; Mauro Feola; Massimo Iacoviello; Roberto Latini; Andrea Mortara; Roberto Valle; Gianfranco Misuraca; Claudio Passino; Serge Masson; Alberto Aimo; Marcello Ciaccio; Marco Migliardi
Journal:  Eur Heart J Suppl       Date:  2017-05-02       Impact factor: 1.803

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.